MEDP vs VEEV
MEDP: Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development. VEEV: Veeva is the dominant cloud software and data platform powering the global life sciences industry from drug development through commercialization, with AI-enhanced solutions and a 16% annual revenue growth trajectory.
Side-by-side fundamentals
| Metric | MEDP | VEEV | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $589.37 | $194.46 | |
| Market cap as of 2026-07-30 | $16.8B | $31.6B | |
| P/E as of 2026-07-30 | 33.40 | 35.74 | MEDP lower |
| PEG as of 2026-07-30 | 2.71 | 1.88 | VEEV lower |
| Net margin as of 2026-07-30 | +17.7% | +28.4% | VEEV higher |
| Gross margin as of 2026-07-30 | +28.8% | +75.0% | VEEV higher |
| Operating margin as of 2026-07-30 | +21.0% | +28.8% | VEEV higher |
| ROE as of 2026-07-30 | +110.1% | +13.4% | MEDP higher |
| ROA as of 2026-07-30 | +24.8% | +11.0% | MEDP higher |
| Debt / equity as of 2026-07-30 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-30 | +24.7% | +16.3% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +20.1% | +14.0% | MEDP higher |
| Beta as of 2026-07-30 | 1.12 | 0.90 | |
| 1-year return as of 2026-07-27 close | +31.7% | -33.0% | MEDP higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.